Gemfibrozil

Gemfibrozil
Clinical data
Trade names	Lopid, others
AHFS/Drugs.com	Monograph
MedlinePlus	a686002
License data	US DailyMed: Gemfibrozil;
Pregnancy; category	AU: B3; ;
Routes of; administration	By mouth
ATC code	C10AB04 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	Close to 100%
Protein binding	95%
Metabolism	Liver (CYP3A4)
Elimination half-life	1.5 hours
Excretion	Kidney 94% ; Feces 6%
Identifiers
	IUPAC name 5-(2,5-dimethylphenoxy)-2,2-dimethyl-pentanoic acid;
CAS Number	25812-30-0 ;
PubChem CID	3463;
IUPHAR/BPS	3439;
DrugBank	DB01241 ;
ChemSpider	3345 ;
UNII	Q8X02027X3;
KEGG	D00334 ;
ChEBI	CHEBI:5296 ;
ChEMBL	ChEMBL457 ;
CompTox Dashboard (EPA)	DTXSID0020652 ;
ECHA InfoCard	100.042.968
Chemical and physical data
Formula	C15H22O3
Molar mass	250.338 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	61 to 63 °C (142 to 145 °F)
	SMILES O=C(O)C(C)(C)CCCOc1cc(ccc1C)C;
	InChI InChI=1S/C15H22O3/c1-11-6-7-12(2)13(10-11)18-9-5-8-15(3,4)14(16)17/h6-7,10H,5,8-9H2,1-4H3,(H,16,17) ; Key:HEMJJKBWTPKOJG-UHFFFAOYSA-N ;
	(verify)

Gemfibrozil, sold under the brand name Lopid among others, is a medication used to treat abnormal blood lipid levels. It is generally less preferred than statins. Use is recommended together with dietary changes and exercise. It is unclear if it changes the risk of heart disease. It is taken by mouth.

Common side effects include headache, dizziness, feeling tired, and intestinal upset. Serious side effects may include angioedema, gallstones, liver problems, and muscle breakdown. Use in pregnancy and breastfeeding is of unclear safety. It belongs to the fibrates group of medications and works by decreasing the breakdown of lipids in fat cells.

Gemfibrozil was patented in 1968, and came into medical use in 1982. It is available as a generic medication. In 2022, it was the 231st most commonly prescribed medication in the United States, with more than 1 million prescriptions.